Slide 1: Indivior PLC Q1 2019 Results
Indivior PLC Q1 2019 Results May 2, 2019
Slide 2: Forward Looking Statements
Forward Looking Statements This announcement contains certain statements that are forward-looking. By their nature, forward-looking statements involve risks and uncertainties as they relate to events or circumstances that may or may not occur in the future. Actual results may differ materially from
Slide 3: Q1 2019 snapshot
Q1 2019 snapshot Operational Highlights Pipeline & Study Progress Financial Performance Double-digit market growth in U.S. market PERSERIS™ (risperidone) for extended Q1 19 vs. Q1 18 (adjusted basis(1)) continues to be mainly driven by release injectable suspension launched Government channels week
Slide 4: DOJ matter
DOJ matter A U.S. federal criminal grand jury investigation of Indivior was initiated in December 2013, and includes marketing and promotion practices, pediatric safety claims, and overprescribing of medication by certain physicians. The U.S. Attorney's Office for the Western District of Virginia se
Slide 5: SUBLOCADE Update
SUBLOCADE™ Update SZ INDIVIOR AS
Slide 6: SUBLOCADE patients injected and closed case performance
Unique SUBLOCADE™ patients injected increasing month over month; Dispense yield now in line with analogs Closed Case Performance (1)(2) Closed case run-rate: 94% 96% 92% 93% 91% 65% 95% 94% 91% Cumulative Launch to 3/31/19 (1) 66% 63% 62% 58% 57% 55% 50% 49% ~65% initial approval rate for SUBOXONE®
Slide 7: SUBLOCADE KPIs – HCP data & patient treatment adherence
SUBLOCADE™ KPIs – HCP data & patient treatment adherence Repeat Injections (All patients with initial injection during March ’18 to Jan ‘19) 2,930 HCPs initiated prescription journeys 100% 80% 73% 1,745 HCPs administered SUBLOCADE™ 60% 40% 56% 45% 39% 35% 31% 26% 415 HCPs administered > 5 patients 2
Slide 8: FY 2019 guidance introduced
FY 2019 guidance introduced FY 2019 Guidance ($ in mil.) Net Revenue $525m - $575m Net (loss) / income ($40m) - $10m Top-line: Expenses: • U.S. Buprenorphine/ Naloxone Film market conditions • OPEX of $440m to $460m, including current Litigation/Investigative ✓ Continued double-digit underlying BMAT
Slide 9: Appendix
Appendix So INDIVIOR
Slide 10: Income statement reconciliation: Q1 2019 vs. Q1 2018
Income statement reconciliation: Q1 2019 vs. Q1 2018 Q1 2019 Q1 2018 Δ Q1 2019 Q1 2019 Y-o-Y Q1 2018 Q1 2018 Adjustments Adjustments Actual Adjusted (adjusted basis) Actual Adjusted ($ in mil. at Actual FX ) Net Revenues 238 238 -6% 255 255 Cost of Sales (37) (37) (24) (24) Gross Profit 201 201 -13%
Slide 11: SUBOXONE Film indication and highlighted safety information
SUBOXONE (BUPRENORPHINE AND NALOXONE) SUBLINGUAL FILM (CIII) INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBOXONE Film is indicated for the treatment of opioid dependence. SUBOXONE Film should be used as part of a complete treatment plan that includes counseling and psychosocial support
Slide 12: SUBLOCADE indication and highlighted safety information
SUBLOCADE (BUPRENORPHINE EXTENDED-RELEASE) INJECTION FOR SUBCUTANEOUS USE (CIII) INDICATION AND HIGHLIGHTED SAFETY INFORMATION INDICATION SUBLOCADE is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a transmucosal buprenorphine-cont
Slide 13: About PERSERIS indication and safety information
ABOUT PERSERIS™ (risperidone) for extended-release injectable suspension INDICATION PERSERISTM (risperidone) is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS See full prescribing information for complete boxed